

Katarina Le Blanc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1780794/publications.pdf>

Version: 2024-02-01

50
papers

10,240
citations

201674

27
h-index

243625

44
g-index

50
all docs

50
docs citations

50
times ranked

11217
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunohistopathology of oral mucosal chronic graft-versus-host disease severity and duration. <i>Oral Diseases</i> , 2023, 29, 3346-3359.	3.0	2
2	Diversity of respiratory parameters and metabolic adaptation to low oxygen tension in mesenchymal stromal cells. <i>Metabolism Open</i> , 2022, 13, 100167.	2.9	2
3	Consensus International Council for Commonality in Blood Banking Automation—International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. <i>Cytotherapy</i> , 2021, 23, 1060-1063.	0.7	15
4	Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. <i>Cell Stem Cell</i> , 2021, 28, 1708-1725.	11.1	114
5	Five-Year Follow-up after Mesenchymal Stromal Cell-based Treatment of Severe Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1051-1055.	5.6	9
6	Challenges for mesenchymal stromal cell therapies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	126
7	Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis—A Phase I Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 2102.	2.4	20
8	Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis. <i>Immunology and Cell Biology</i> , 2018, 96, 820-830.	2.3	38
9	MSCs—cells with many sides. <i>Cytotherapy</i> , 2018, 20, 273-278.	0.7	91
10	Stromal progenitor cell modulation by thalidomide in the treatment of oral chronic graft-versus-host disease. <i>Cytotherapy</i> , 2018, 20, 755-758.	0.7	1
11	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
12	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 677-683.	2.0	12
13	Commentary: Role of Mesenchymal Stromal Cell-Mediated Crosstalk with Macrophages in Graft-versus-Host Disease and Tissue Repair. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 861-862.	2.0	7
14	Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. <i>Stem Cells</i> , 2016, 34, 516-521.	3.2	39
15	Heparinization of cell surfaces with short peptide-conjugated PEG-lipid regulates thromboinflammation in transplantation of human MSCs and hepatocytes. <i>Acta Biomaterialia</i> , 2016, 35, 194-205.	8.3	24
16	Wnt/ β -Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. <i>Stem Cell Reports</i> , 2016, 6, 607-617.	4.8	20
17	Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1485-1495.	3.3	51
18	MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC. <i>Scientific Reports</i> , 2016, 6, 29160.	3.3	43

#	ARTICLE	IF	CITATIONS
19	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 3849-3859.	7.0	109
20	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 3374-3374.	1.4	0
21	Enhanced oral healing following local mesenchymal stromal cell therapy. <i>Oral Oncology</i> , 2015, 51, e97-e99.	1.5	3
22	MSCs: Scientific Support for Multiple Therapies. <i>Stem Cells International</i> , 2015, 2015, 1-2.	2.5	12
23	Mesenchymal stromal cells and the innate immune response. <i>Immunology Letters</i> , 2015, 168, 140-146.	2.5	204
24	Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling. <i>Blood</i> , 2015, 125, 3432-3436.	1.4	76
25	In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. <i>Stem Cells Translational Medicine</i> , 2015, 4, 1199-1213.	3.3	131
26	Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2398-2398.	1.4	0
27	Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells?. <i>PLoS ONE</i> , 2014, 9, e85040.	2.5	61
28	Defined serum-free media for in vitro expansion of adipose-derived mesenchymal stem cells. <i>Cytotherapy</i> , 2014, 16, 915-926.	0.7	48
29	CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. <i>Blood</i> , 2014, 124, 750-760.	1.4	206
30	Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation. <i>Onc Immunology</i> , 2013, 2, e25009.	4.6	13
31	Multipotent mesenchymal stromal cells and the innate immune system. <i>Nature Reviews Immunology</i> , 2012, 12, 383-396.	22.7	811
32	Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1108-1115.	2.0	100
33	Human Mesenchymal Stem Cells Elicit Complement Activation in Human Blood.. <i>Blood</i> , 2009, 114, 4580-4580.	1.4	0
34	Persistence of Human Parvovirus B19 in Multipotent Mesenchymal Stromal Cells Expressing the Erythrocyte P Antigen: Implications for Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1172-1179.	2.0	31
35	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. <i>Lancet, The</i> , 2008, 371, 1579-1586.	13.7	2,474
36	HLA Mismatched MSC Suppress T Lymphocyte Allo responses in Vitro and Do Not Induce Immunological Memory in Recipients of MSC Infusion. <i>Blood</i> , 2008, 112, 4740-4740.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Generation of Immunosuppressive Mesenchymal Stem Cells in Allogeneic Human Serum. Transplantation, 2007, 84, 1055-1059.	1.0	57
38	Immune Escape and Suppression by Human Mesenchymal Stem Cells. , 2006, , 233-245.		0
39	Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Current Opinion in Immunology, 2006, 18, 586-591.	5.5	202
40	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 2918-2918.	1.4	4
41	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 5304-5304.	1.4	8
42	Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta. Transplantation, 2005, 79, 1607-1614.	1.0	397
43	Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 321-334.	2.0	429
44	Mesenchymal Stem Cells for Treatment of Severe Acute and Extensive Chronic Graft-Versus-Host Disease.. Blood, 2005, 106, 143-143.	1.4	3
45	Transplantation of Haplo-Identical Bone Marrow-Derived Mesenchymal Stem Cells Together with Hematopoietic Stem Cells To Promote Engraftment in Children. A Phase I/II Multicenter Study.. Blood, 2005, 106, 2911-2911.	1.4	0
46	Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation. Haematologica, 2005, 90, 438.	3.5	21
47	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, The, 2004, 363, 1439-1441.	13.7	2,534
48	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 1014-1020.	1.0	59
49	HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology, 2003, 31, 890-896.	0.4	1,510
50	A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica, 2003, 88, 1044-52.	3.5	62